scholarly journals Non-Surgical Correction of Nasal Dorsum and Tip in Primary Cases

2019 ◽  
Vol 46 (2) ◽  
pp. 47-50
Author(s):  
Y. P. Yordanov ◽  
A. Shef
Keyword(s):  
Patient Reported Outcomes ◽  
Major Complication ◽  
Aesthetic Medicine ◽  
Non Invasive ◽  
High Satisfaction ◽  
Retrospective Clinical Study ◽  
Patient Reported ◽  
High Satisfaction Rate ◽  
Preliminary Study ◽  
Non Surgical Treatment

Abstract Nowadays, minimally invasive and non-invasive approaches in aesthetic medicine are increasingly popular and non-surgical rhinoplasty is one of the procedures with rising demand worldwide. In Bulgaria, this procedure seems to be uncommonly performed, since there are no reports in the local scientific literature. The aim of this preliminary study was to briefly explore the possibilities of hyaluronic acid (HA) fillers for correcting three of the most common nasal deformities – dorsal hump, under-projected and under-rotated nasal tip in primary cases. In order to accomplish this objective, a retrospective clinical study was conducted encompassing 11 cases of the authors’ practices with the above mentioned nasal irregularities and no previous surgical/non-surgical treatment. The analysis of patient-reported outcomes suggested a high satisfaction rate, with no major complication in the series. The HA filler has shown to be safe, relatively easily applicable and highly effective for camouflaging nasal deformities. A special emphasis was put on the patient safety and ten golden rules for staying out of trouble were given.

scholarly journals Acceptability of no-test medical abortion provided via telemedicine: analysis of patient-reported outcomes

2021 ◽  
pp. bmjsrh-2020-200954
Author(s):  
Chelsey Porter Erlank ◽  
Jonathan Lord ◽  
Kathryn Church
Keyword(s):  
Patient Reported Outcomes ◽  
Medical Abortion ◽  
Patient Reported Outcome Measures ◽  
Patient Reported Outcome ◽  
Post Procedure ◽  
High Satisfaction ◽  
First Choice ◽  
Patient Reported ◽  
At Home

IntroductionThe English government approved both stages of early medical abortion (EMA), using mifepristone and misoprostol under 10 weeks’ gestation, for at-home use on 30 March 2020. MSI Reproductive Choices UK (MSUK), one of the largest providers of abortion services in England, launched a no-test telemedicine EMA pathway on 6 April 2020. The objectives of this study were to report key patient-reported outcome measures and to assess whether our sample was representative of the whole population receiving no-test telemedicine EMA.MethodsA sample of all MSUK’s telemedicine EMA patients between April and August 2020 were invited to opt in to a follow-up call to answer clinical and satisfaction questions. A total of 1243 (13.7% of all telemedicine EMAs) were successfully followed-up, on average within 5 days post-procedure.ResultsPatients reported high confidence in telemedicine EMA and high satisfaction with the convenience, privacy and ease of managing their abortion at home. The sample responding were broadly equivalent to the whole population receiving telemedicine. No patient reported that they were unable to consult privately. The majority (1035, 83%) of patients reported preferring the telemedicine pathway, with 824 (66%) indicating that they would choose telemedicine again if COVID-19 were no longer an issue.ConclusionsTelemedicine EMA is a valued, private, convenient and more accessible option that is highly acceptable for patients seeking an abortion, especially those for whom in-clinic visits are logistically or emotionally challenging. Evidence that this pathway would be a first choice again in future for most patients supports the case to make telemedicine EMA permanent.

scholarly journals Fibrosis non-invasive tests capture changes in patient-reported outcomes of patients with advanced non-alcoholic steatohepatitis

2020 ◽  
Vol 73 ◽  
pp. S171
Author(s):  
Zobair Younossi ◽  
Stephen Harrison ◽  
Quentin Anstee ◽  
Eric Lawitz ◽  
Vincent Wai-Sun Wong ◽  
...  
Keyword(s):  
Patient Reported Outcomes ◽  
Non Invasive ◽  
Alcoholic Steatohepatitis ◽  
Patient Reported

scholarly journals Oncology patient preferences in reporting on symptoms

2020 ◽  
Vol 7 (1) ◽  
pp. 11
Author(s):  
Alyssa L. Peechatka ◽  
Millie Gerzon ◽  
Jenny J. Ly ◽  
Susan M. Dallabrida
Keyword(s):  
Clinical Trials ◽  
Cancer Diagnosis ◽  
Patient Reported Outcomes ◽  
Online Survey ◽  
Data Capture ◽  
Oncology Patient ◽  
Patient Reported ◽  
Oncology Clinical Trials ◽  
Preliminary Study ◽  
Patient Burden

<p><strong>Background:</strong> Collecting patient reported outcomes (PROs) in oncology clinical trials is becoming increasingly important. However, there is limited consensus on the most appropriate frequency of PRO administration in oncology trials.  The aim of this preliminary study is to examine the perspective of participants with a cancer diagnosis on the importance of completing PROs and to identify at what frequency participants prefer to report on their cancer-related symptoms.</p><p class="abstract"><strong>Methods:</strong> 166 participants with a self-reported cancer diagnosis completed a multiple-choice online survey regarding perceptions of symptom importance and reporting preferences.</p><p class="abstract"><strong>Results:</strong> When asked about the benefit of reporting oncology-related symptoms daily, 44% of participants indicated there would be “very much” a benefit, 29% indicated there would be “quite a bit” of benefit, and 17% indicated there would be “somewhat” of a benefit. When asked about how frequently they would prefer to report symptoms, 41% of participants preferred “as they occur,” 36% preferred “once a day,” 18% preferred “once a week,” 4% preferred “twice a day,” and 1% preferred “every 4 hours”.</p><p class="abstract"><strong>Conclusions: </strong>PROs in oncology clinical research are most often collected at weekly, monthly, or longer intervals; however, meaningful fluctuations in cancer-related symptoms can occur more frequently. While concerns regarding patient burden are often raised to support infrequent reporting, these data suggest that participants would like to report symptoms with greater frequency, as episodic and daily reporting options were most popular. Based on these data, more frequent PRO data capture is not only feasible but perceived as important by individuals with cancer.</p>

scholarly journals Comparison of patient-reported outcomes between immediately and conventionally loaded mandibular two-implant overdentures: A preliminary study

2016 ◽  
Vol 60 (3) ◽  
pp. 185-192 ◽  
Author(s):  
Yuri Omura ◽  
Manabu Kanazawa ◽  
Daisuke Sato ◽  
Shohei Kasugai ◽  
Shunsuke Minakuchi
Keyword(s):  
Patient Reported Outcomes ◽  
Patient Reported ◽  
Preliminary Study

scholarly journals A Mobile Patient-Facing Application for Tracking Patient-Reported Outcomes in Head and Neck Cancer Survivors: A Single-Arm Feasibility Study (Preprint)

2020 ◽  
Author(s):  
Sewit Teckie ◽  
Jeffrey Solomon ◽  
Karthik Kadapa ◽  
Keisy Sanchez ◽  
David Orner ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Cancer Survivors ◽  
Head And Neck ◽  
Neck Cancer ◽  
Patient Reported Outcomes ◽  
Perceived Usefulness ◽  
Post Intervention ◽  
High Satisfaction ◽  
System Usability Scale ◽  
Patient Reported

BACKGROUND Patients with head and neck cancer (HNC) frequently experience disease-related symptoms and treatment adverse effects that impact their overall quality of life. Cancer-specific mobile health (mHealth) applications (app) for patient-related outcomes (PROs) allow patients to communicate with their clinicians and proactively track their symptoms, which has been shown to improve clinical management and disease outcomes. OBJECTIVE The purpose of this study was to evaluate the feasibility of LogPALTM, a novel iOS-based mHealth app designed to help HNC survivors track and manage their post-treatment symptoms. METHODS Patients who completed curative treatment for HNC in the preceding 24 months were recruited from two clinical sites within a single institution. Upon enrollment, participants completed a brief sociodemographic survey, downloaded the app onto their iOS device, and were asked to complete a series of biweekly questionnaires (based on the Patient Reported Outcomes version of the Common Terminology Criteria of Adverse Events (PRO-CTCAE) via the app for an eight-week study period. The primary feasibility end-points included: retention (retaining > 80% of enrolled participants for the duration of the study period), adherence (> 50% of participants completing 100% of questionnaires over the study period), and usability (a mean System Usability Scale (SUS) score of > 68). Additional post-intervention questions were collected to assess perceived usefulness, acceptance and overall satisfaction. RESULTS Between January and October 2019, a total of 38 participants enrolled in the study. Three participants dropped out, and three were classified as non-users. The remaining 32 (86.8%) were eligible for analysis. Mean age was 58 years ([ranged 24-72], 81.3% male). Overall, 375 of 512 (73.2%) questionnaires were completed, with 17 (53.1%) participants adherent. Participant-reported usability was acceptable; mean SUS score was 71.9 (95% CI 64.3 – 79.5) with high satisfaction of LogPALTM usefulness and likelihood to recommend to other cancer survivors. CONCLUSIONS This single-arm prospective pilot study showed that LogPALTM is a feasible, regularly used, accepted app for HNC survivors, justifying a full-scale pilot. Based on findings from this study, future iterations will aim to improve usability and test intervention efficacy.

The patient' view of CPAP treatment: A preliminary study of patient-reported outcomes

2015 ◽  
Vol 16 ◽  
pp. S50
Author(s):  
K. Conrod ◽  
D. Rizzo ◽  
D. Tran ◽  
R. Grad ◽  
A. Pavilanis ◽  
...  
Keyword(s):  
Patient Reported Outcomes ◽  
Cpap Treatment ◽  
Patient Reported ◽  
Preliminary Study

79 Non-invasive detection of endometriosis implants with MRI and patient reported outcomes

2021 ◽  
Vol 224 (6) ◽  
pp. S794
Author(s):  
V.H. Flatow ◽  
J. Huntley ◽  
C. Ascher-Walsh ◽  
B. Friedman ◽  
S. Khalil
Keyword(s):  
Patient Reported Outcomes ◽  
Non Invasive ◽  
Patient Reported

Mid-term survivorship and patient-reported outcomes of robotic-arm assisted partial knee arthroplasty

2020 ◽  
Vol 102-B (1) ◽  
pp. 108-116 ◽  
Author(s):  
Joost A. Burger ◽  
Laura J. Kleeblad ◽  
Niels Laas ◽  
Andrew D. Pearle
Keyword(s):  
Knee Arthroplasty ◽  
Patient Reported Outcomes ◽  
Robotic Arm ◽  
Modes Of Failure ◽  
Partial Knee Arthroplasty ◽  
Component Design ◽  
High Satisfaction ◽  
Patient Reported ◽  
Component Loosening ◽  
Lateral Uka

Aims Limited evidence is available on mid-term outcomes of robotic-arm assisted (RA) partial knee arthroplasty (PKA). Therefore, the purpose of this study was to evaluate mid-term survivorship, modes of failure, and patient-reported outcomes of RA PKA. Methods A retrospective review of patients who underwent RA PKA between June 2007 and August 2016 was performed. Patients received a fixed-bearing medial or lateral unicompartmental knee arthroplasty (UKA), patellofemoral arthroplasty (PFA), or bicompartmental knee arthroplasty (BiKA; PFA plus medial UKA). All patients completed a questionnaire regarding revision surgery, reoperations, and level of satisfaction. Knee Injury and Osteoarthritis Outcome Scores (KOOS) were assessed using the KOOS for Joint Replacement Junior survey. Results Mean follow-up was 4.7 years (2.0 to 10.8). Five-year survivorship of medial UKA (n = 802), lateral UKA (n = 171), and PFA/BiKA (n = 35/10) was 97.8%, 97.7%, and 93.3%, respectively. Component loosening and progression of osteoarthritis (OA) were the most common reasons for revision. Mean KOOS scores after medial UKA, lateral UKA, and PFA/BiKA were 84.3 (SD 15.9), 85.6 (SD 14.3), and 78.2 (SD 14.2), respectively. The vast majority of the patients reported high satisfaction levels after RA PKA. Subgroup analyses suggested tibial component design, body mass index (BMI), and age affects RA PKA outcomes. Five-year survivorship was 98.4% (95% confidence interval (CI) 97.2 to 99.5) for onlay medial UKA (n = 742) and 99.1% (95% CI 97.9 to 100) for onlay medial UKA in patients with a BMI < 30 kg/m2 (n = 479). Conclusion This large single-surgeon study showed high mid-term survivorship, satisfaction levels, and functional outcomes in RA UKA using metal-backed tibial onlay components. In addition, favourable results were reported in RA PFA and BiKA. Cite this article: Bone Joint J 2020;102-B(1):108–116

Sign in / Sign up

Export Citation Format

Share Document